These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20537438)

  • 1. Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods.
    Cheng F; Xu Z; Liu G; Tang Y
    Eur J Med Chem; 2010 Aug; 45(8):3459-71. PubMed ID: 20537438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists.
    Ivanov AA; Baskin II; Palyulin VA; Piccagli L; Baraldi PG; Zefirov NS
    J Med Chem; 2005 Nov; 48(22):6813-20. PubMed ID: 16250640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-specific binding and activation of the human adenosine A(2B) receptor.
    Thimm D; Schiedel AC; Sherbiny FF; Hinz S; Hochheiser K; Bertarelli DC; Maass A; Müller CE
    Biochemistry; 2013 Jan; 52(4):726-40. PubMed ID: 23286920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics simulations reveal insights into key structural elements of adenosine receptors.
    Rodríguez D; Piñeiro Á; Gutiérrez-de-Terán H
    Biochemistry; 2011 May; 50(19):4194-208. PubMed ID: 21480628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-affinity relationships of adenosine A2B receptor ligands.
    Beukers MW; Meurs I; Ijzerman AP
    Med Res Rev; 2006 Sep; 26(5):667-98. PubMed ID: 16847822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The four cysteine residues in the second extracellular loop of the human adenosine A2B receptor: role in ligand binding and receptor function.
    Schiedel AC; Hinz S; Thimm D; Sherbiny F; Borrmann T; Maass A; Müller CE
    Biochem Pharmacol; 2011 Aug; 82(4):389-99. PubMed ID: 21620804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor.
    Peeters MC; van Westen GJ; Guo D; Wisse LE; Müller CE; Beukers MW; Ijzerman AP
    FASEB J; 2011 Feb; 25(2):632-43. PubMed ID: 21030693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.
    Borrmann T; Hinz S; Bertarelli DC; Li W; Florin NC; Scheiff AB; Müller CE
    J Med Chem; 2009 Jul; 52(13):3994-4006. PubMed ID: 19569717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
    Tabrizi MA; Baraldi PG; Preti D; Romagnoli R; Saponaro G; Baraldi S; Moorman AR; Zaid AN; Varani K; Borea PA
    Bioorg Med Chem; 2008 Mar; 16(5):2419-30. PubMed ID: 18077171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships.
    Fernández F; Caamaño O; Isabel Nieto M; López C; García-Mera X; Stefanachi A; Nicolotti O; Isabel Loza M; Brea J; Esteve C; Segarra V; Vidal B; Carotti A
    Bioorg Med Chem; 2009 May; 17(10):3618-29. PubMed ID: 19398343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative structure activity relationship and pharmacophore studies of adenosine receptor A2B inhibitors.
    Joseph TB; Suneel Kumar BV; Santhosh B; Kriti S; Pramod AB; Ravikumar M; Kishore M
    Chem Biol Drug Des; 2008 Nov; 72(5):395-408. PubMed ID: 19012575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor.
    Stefanachi A; Brea JM; Cadavid MI; Centeno NB; Esteve C; Loza MI; Martinez A; Nieto R; Raviña E; Sanz F; Segarra V; Sotelo E; Vidal B; Carotti A
    Bioorg Med Chem; 2008 Mar; 16(6):2852-69. PubMed ID: 18226909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships.
    Stefanachi A; Nicolotti O; Leonetti F; Cellamare S; Campagna F; Loza MI; Brea JM; Mazza F; Gavuzzo E; Carotti A
    Bioorg Med Chem; 2008 Nov; 16(22):9780-9. PubMed ID: 18938084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding.
    Kanagarajadurai K; Malini M; Bhattacharya A; Panicker MM; Sowdhamini R
    Mol Biosyst; 2009 Dec; 5(12):1877-88. PubMed ID: 19763327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
    Axe FU; Bembenek SD; Szalma S
    J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A structural study of new potent and selective antagonists to the A2B adenosine receptor.
    Ferretti V; Pretto L; Tabrizi MA; Bertolasi V
    Acta Crystallogr B; 2005 Oct; 61(Pt 5):569-76. PubMed ID: 16186657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
    Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
    ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homology modeling and docking evaluation of aminergic G protein-coupled receptors.
    McRobb FM; Capuano B; Crosby IT; Chalmers DK; Yuriev E
    J Chem Inf Model; 2010 Apr; 50(4):626-37. PubMed ID: 20187660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
    Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
    Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.
    Moro S; Braiuca P; Deflorian F; Ferrari C; Pastorin G; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
    J Med Chem; 2005 Jan; 48(1):152-62. PubMed ID: 15634009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.